A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Ciudad Autonoma de Buenos Aires, Buenos Aires 1430, Argentina
CABA, 1426, Argentina
KYS, 70029, Finland
Wilton, CORK 0, Ireland
Turin, Piedmont 10126, Italy
Untrecht, 3584CX, Netherlands
Doniostia - San Sebastian, 20014, Spain
Santiago Compostela, 15706, Spain
Tauton, TA1 5DA, United Kingdom